Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections
Antimicrobial peptides (AMPs), also known as host defense peptides (HDPs), are important effector immune defense molecules in multicellular organisms. AMPs exert their antimicrobial activities through several mechanisms; thus far, induction of drug resistance through AMPs has been regarded as unlike...
Gespeichert in:
| Veröffentlicht in: | Medicinal research reviews 2022-07, Vol.42 (4), p.1377-1422 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1422 |
|---|---|
| container_issue | 4 |
| container_start_page | 1377 |
| container_title | Medicinal research reviews |
| container_volume | 42 |
| creator | Zhu, Yiyun Hao, Weijing Wang, Xia Ouyang, Jianhong Deng, Xinyi Yu, Haining Wang, Yipeng |
| description | Antimicrobial peptides (AMPs), also known as host defense peptides (HDPs), are important effector immune defense molecules in multicellular organisms. AMPs exert their antimicrobial activities through several mechanisms; thus far, induction of drug resistance through AMPs has been regarded as unlikely. Therefore, they have great potential as new generation antimicrobial agents. To date, more than 30 AMP‐related drugs are in the clinical trial phase. In recent years, studies show that some AMPs and conventional antibiotics have synergistic effects. The combined use of AMPs and antibiotics can kill drug‐resistant pathogens, prevent drug resistance, and significantly improve the therapeutic effects of antibiotics. In this review, we discuss the progress in synergistic studies on AMPs and conventional antibiotics. An overview of the current understanding of the functional scope of AMPs, ongoing clinical trials, and challenges in the development processes are also presented. |
| doi_str_mv | 10.1002/med.21879 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2616960302</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2616960302</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3539-49ffd9a7a5fd2f3be4aec8a4c856e9e748c4448daceaf1da5af0ea166c7ab52f3</originalsourceid><addsrcrecordid>eNp1kc1u1TAQRi0EopfCghdAlthQidvaiePYy6qUH6mIDayjiTMurpL4Yjugu-sj8Ix9EibcdoPEyqP5js9iPsZeSnEqhajOJhxOK2la-4htpLBmK2VlHrONkDTrumqO2LOcb4SQspH1U3ZUK2uUtnbDbs_nEqbgUuwDjHyHuxIGzG-5i_NPpCzOtAYa-hBLcJTAPPDyHUPieT9jug6Z9nwpYQxlz31Ma8pLQigTGXj0fEjL9d3t74SZYJLxMHt0qzw_Z088jBlf3L_H7Nv7y68XH7dXXz58uji_2rq6qe1WWe8HCy00fqh83aMCdAaUM41Gi60yTillBnAIXg7QgBcIUmvXQt_Qj2P25uDdpfhjwVy6KWSH4wgzxiV3lZbaalGLitDX_6A3cUl0h5VqlW6FrQxRJweKbpdzQt_tUpgg7TspurWWjmrp_tZC7Kt749Kv2wfyoQcCzg7ArzDi_v-m7vPlu4PyD3SFnAQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2674670928</pqid></control><display><type>article</type><title>Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zhu, Yiyun ; Hao, Weijing ; Wang, Xia ; Ouyang, Jianhong ; Deng, Xinyi ; Yu, Haining ; Wang, Yipeng</creator><creatorcontrib>Zhu, Yiyun ; Hao, Weijing ; Wang, Xia ; Ouyang, Jianhong ; Deng, Xinyi ; Yu, Haining ; Wang, Yipeng</creatorcontrib><description>Antimicrobial peptides (AMPs), also known as host defense peptides (HDPs), are important effector immune defense molecules in multicellular organisms. AMPs exert their antimicrobial activities through several mechanisms; thus far, induction of drug resistance through AMPs has been regarded as unlikely. Therefore, they have great potential as new generation antimicrobial agents. To date, more than 30 AMP‐related drugs are in the clinical trial phase. In recent years, studies show that some AMPs and conventional antibiotics have synergistic effects. The combined use of AMPs and antibiotics can kill drug‐resistant pathogens, prevent drug resistance, and significantly improve the therapeutic effects of antibiotics. In this review, we discuss the progress in synergistic studies on AMPs and conventional antibiotics. An overview of the current understanding of the functional scope of AMPs, ongoing clinical trials, and challenges in the development processes are also presented.</description><identifier>ISSN: 0198-6325</identifier><identifier>EISSN: 1098-1128</identifier><identifier>DOI: 10.1002/med.21879</identifier><identifier>PMID: 34984699</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Anti-Infective Agents - therapeutic use ; Antibiotics ; Antimicrobial agents ; Antimicrobial Cationic Peptides - pharmacology ; Antimicrobial Cationic Peptides - therapeutic use ; antimicrobial mechanism ; Antimicrobial Peptides ; antimicrobial peptides (AMPs) ; conventional antibiotics ; Drug resistance ; Humans ; Multidrug resistant organisms ; Peptides ; synergy</subject><ispartof>Medicinal research reviews, 2022-07, Vol.42 (4), p.1377-1422</ispartof><rights>2021 Wiley Periodicals LLC</rights><rights>2021 Wiley Periodicals LLC.</rights><rights>2022 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3539-49ffd9a7a5fd2f3be4aec8a4c856e9e748c4448daceaf1da5af0ea166c7ab52f3</citedby><cites>FETCH-LOGICAL-c3539-49ffd9a7a5fd2f3be4aec8a4c856e9e748c4448daceaf1da5af0ea166c7ab52f3</cites><orcidid>0000-0003-1385-4470</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmed.21879$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmed.21879$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34984699$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhu, Yiyun</creatorcontrib><creatorcontrib>Hao, Weijing</creatorcontrib><creatorcontrib>Wang, Xia</creatorcontrib><creatorcontrib>Ouyang, Jianhong</creatorcontrib><creatorcontrib>Deng, Xinyi</creatorcontrib><creatorcontrib>Yu, Haining</creatorcontrib><creatorcontrib>Wang, Yipeng</creatorcontrib><title>Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections</title><title>Medicinal research reviews</title><addtitle>Med Res Rev</addtitle><description>Antimicrobial peptides (AMPs), also known as host defense peptides (HDPs), are important effector immune defense molecules in multicellular organisms. AMPs exert their antimicrobial activities through several mechanisms; thus far, induction of drug resistance through AMPs has been regarded as unlikely. Therefore, they have great potential as new generation antimicrobial agents. To date, more than 30 AMP‐related drugs are in the clinical trial phase. In recent years, studies show that some AMPs and conventional antibiotics have synergistic effects. The combined use of AMPs and antibiotics can kill drug‐resistant pathogens, prevent drug resistance, and significantly improve the therapeutic effects of antibiotics. In this review, we discuss the progress in synergistic studies on AMPs and conventional antibiotics. An overview of the current understanding of the functional scope of AMPs, ongoing clinical trials, and challenges in the development processes are also presented.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Antimicrobial Cationic Peptides - pharmacology</subject><subject>Antimicrobial Cationic Peptides - therapeutic use</subject><subject>antimicrobial mechanism</subject><subject>Antimicrobial Peptides</subject><subject>antimicrobial peptides (AMPs)</subject><subject>conventional antibiotics</subject><subject>Drug resistance</subject><subject>Humans</subject><subject>Multidrug resistant organisms</subject><subject>Peptides</subject><subject>synergy</subject><issn>0198-6325</issn><issn>1098-1128</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1u1TAQRi0EopfCghdAlthQidvaiePYy6qUH6mIDayjiTMurpL4Yjugu-sj8Ix9EibcdoPEyqP5js9iPsZeSnEqhajOJhxOK2la-4htpLBmK2VlHrONkDTrumqO2LOcb4SQspH1U3ZUK2uUtnbDbs_nEqbgUuwDjHyHuxIGzG-5i_NPpCzOtAYa-hBLcJTAPPDyHUPieT9jug6Z9nwpYQxlz31Ma8pLQigTGXj0fEjL9d3t74SZYJLxMHt0qzw_Z088jBlf3L_H7Nv7y68XH7dXXz58uji_2rq6qe1WWe8HCy00fqh83aMCdAaUM41Gi60yTillBnAIXg7QgBcIUmvXQt_Qj2P25uDdpfhjwVy6KWSH4wgzxiV3lZbaalGLitDX_6A3cUl0h5VqlW6FrQxRJweKbpdzQt_tUpgg7TspurWWjmrp_tZC7Kt749Kv2wfyoQcCzg7ArzDi_v-m7vPlu4PyD3SFnAQ</recordid><startdate>202207</startdate><enddate>202207</enddate><creator>Zhu, Yiyun</creator><creator>Hao, Weijing</creator><creator>Wang, Xia</creator><creator>Ouyang, Jianhong</creator><creator>Deng, Xinyi</creator><creator>Yu, Haining</creator><creator>Wang, Yipeng</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1385-4470</orcidid></search><sort><creationdate>202207</creationdate><title>Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections</title><author>Zhu, Yiyun ; Hao, Weijing ; Wang, Xia ; Ouyang, Jianhong ; Deng, Xinyi ; Yu, Haining ; Wang, Yipeng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3539-49ffd9a7a5fd2f3be4aec8a4c856e9e748c4448daceaf1da5af0ea166c7ab52f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Antimicrobial Cationic Peptides - pharmacology</topic><topic>Antimicrobial Cationic Peptides - therapeutic use</topic><topic>antimicrobial mechanism</topic><topic>Antimicrobial Peptides</topic><topic>antimicrobial peptides (AMPs)</topic><topic>conventional antibiotics</topic><topic>Drug resistance</topic><topic>Humans</topic><topic>Multidrug resistant organisms</topic><topic>Peptides</topic><topic>synergy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Yiyun</creatorcontrib><creatorcontrib>Hao, Weijing</creatorcontrib><creatorcontrib>Wang, Xia</creatorcontrib><creatorcontrib>Ouyang, Jianhong</creatorcontrib><creatorcontrib>Deng, Xinyi</creatorcontrib><creatorcontrib>Yu, Haining</creatorcontrib><creatorcontrib>Wang, Yipeng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Medicinal research reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Yiyun</au><au>Hao, Weijing</au><au>Wang, Xia</au><au>Ouyang, Jianhong</au><au>Deng, Xinyi</au><au>Yu, Haining</au><au>Wang, Yipeng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections</atitle><jtitle>Medicinal research reviews</jtitle><addtitle>Med Res Rev</addtitle><date>2022-07</date><risdate>2022</risdate><volume>42</volume><issue>4</issue><spage>1377</spage><epage>1422</epage><pages>1377-1422</pages><issn>0198-6325</issn><eissn>1098-1128</eissn><abstract>Antimicrobial peptides (AMPs), also known as host defense peptides (HDPs), are important effector immune defense molecules in multicellular organisms. AMPs exert their antimicrobial activities through several mechanisms; thus far, induction of drug resistance through AMPs has been regarded as unlikely. Therefore, they have great potential as new generation antimicrobial agents. To date, more than 30 AMP‐related drugs are in the clinical trial phase. In recent years, studies show that some AMPs and conventional antibiotics have synergistic effects. The combined use of AMPs and antibiotics can kill drug‐resistant pathogens, prevent drug resistance, and significantly improve the therapeutic effects of antibiotics. In this review, we discuss the progress in synergistic studies on AMPs and conventional antibiotics. An overview of the current understanding of the functional scope of AMPs, ongoing clinical trials, and challenges in the development processes are also presented.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34984699</pmid><doi>10.1002/med.21879</doi><tpages>46</tpages><orcidid>https://orcid.org/0000-0003-1385-4470</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0198-6325 |
| ispartof | Medicinal research reviews, 2022-07, Vol.42 (4), p.1377-1422 |
| issn | 0198-6325 1098-1128 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2616960302 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Anti-Infective Agents - therapeutic use Antibiotics Antimicrobial agents Antimicrobial Cationic Peptides - pharmacology Antimicrobial Cationic Peptides - therapeutic use antimicrobial mechanism Antimicrobial Peptides antimicrobial peptides (AMPs) conventional antibiotics Drug resistance Humans Multidrug resistant organisms Peptides synergy |
| title | Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T01%3A40%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antimicrobial%20peptides,%20conventional%20antibiotics,%20and%20their%20synergistic%20utility%20for%20the%20treatment%20of%20drug%E2%80%90resistant%20infections&rft.jtitle=Medicinal%20research%20reviews&rft.au=Zhu,%20Yiyun&rft.date=2022-07&rft.volume=42&rft.issue=4&rft.spage=1377&rft.epage=1422&rft.pages=1377-1422&rft.issn=0198-6325&rft.eissn=1098-1128&rft_id=info:doi/10.1002/med.21879&rft_dat=%3Cproquest_cross%3E2616960302%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2674670928&rft_id=info:pmid/34984699&rfr_iscdi=true |